SEC Form 4 · accession 0001144204-17-002042
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anand Mehra
Director
Period of report
Jan 10, 2017
Accepted (ET)
Jan 12, 2017 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 10, 2017 | S | 750,000 | $28.2511 | D | 1,539,480 | I | By Funds |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The Reporting Person is a managing member of SM VIII and may be deemed to share voting and dispositive power over the shares held by SVP VIII. The Reporting Person disclaims beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.